Brequinar Sodium is a dihydroorotate dehydrogenase inhibitor that blocks de novo pyrimidine synthesis, historically investigated as an immunosuppressant and antineoplastic, with renewed interest as a broad-spectrum antiviral candidate. Simson Pharma's Brequinar Sodium reference standard supports this evolving research application.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Brequinar sodium Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.